|
Commercial Insight - CNS Market Overview - Commercial dynamics and outlook of the neurology, pain and psychiatry market sectors (Datamonitor)
Market: Healthcare and Medical
Published Date: 17/04/2008
Market Research Report Title: Commercial Insight - CNS Market Overview - Commercial dynamics and outlook of the neurology, pain and psychiatry market sectors
Table of Contents: View
Report Type: Market Report
Country: Global
Number of Pages: 411
|
Enquire about Report |
Summary: Introduction
The market for CNS drugs across the 7MM was worth a substantial $95.5 billion, accounting for a 21.4% share of the total pharmaceutical market value in 2007. Despite stalling R&D productivity and the genericization of the majority of leading CNS blockbuster brands, the market continues to offer a wealth of lucrative opportunities for all types of drug manufacturer.
Scope
An inter and intra-sector view of the CNS market and its key components—neurology, pain, and psychiatry—in Japan, the US, and 5EUMarket size, structure, key brands, and company prescription sales value and volume data analyzed in each sectorTop-line analysis of key indications in each sector, drawing on key insights with disease-specific market trends and forecastsAssessment of the commercial viability of the future CNS market with strategic recommendations to aid R&D decisionsHighlights
When comparing the three CNS sectors the pain sector is by far the largest by volume prescriptions, accounting for 53.5% of the 2007 CNS market total. However, in terms of value, psychiatry is the dominant sector, accounting for over 48% of total CNS sales, whereas neurology is the fastest growing sector.On top of growing patient numbers, there remains a comparatively high unmet need in treatment of many neurological diseases. With the potential of being one of the most lucrative therapy areas in the future pharmaceutical Industry, Alzheimer’s disease offers the greatest commercial opportunity for pharmaceutical companies in neurology.Currently dominated by Big Pharma players and a number of multi-blockbuster antidepressant and antipsychotic brands, the psychiatry market value will begin to decrease from 2010 onwards as key patents begin to expire. Nevertheless, continued investment will eventually see the R&D pipeline yield new improved agents with blockbuster potential.Reasons to Purchase
Identify the commercial and clinical characteristics for the major CNS markets across Japan, the US and M5EUUnderstand the future market landscape to align R&D decisions and target the indications that offer the most opportunity to your companyQuantify the key historical company and brand dynamics that have shaped the three CNS market sectors
Reports are normally delivered on the same day, via email, if purchased by debit/credit card. Reports purchased by invoice will be released when payment has been received. When you place an order through Google Checkout, Google Checkout will display a price approximation in your local currency. Keep in mind that you'll still be charged in the currency displayed on companiesandmarkets.com. Your debit/credit card company might convert the charge to your local currency and may also add additional fees that are not reflected in the approximate price displayed.
www.companiesandmarkets.com is a central source of market research reports from the world’s leading analysts and report publishers. Companiesandmarkets.com contains a comprehensive range of specialised market research reports from leading publishers for all market sectors.
